These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 25446253)

  • 21. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
    Stühmer T; Zöllinger A; Siegmund D; Chatterjee M; Grella E; Knop S; Kortüm M; Unzicker C; Jensen MR; Quadt C; Chène P; Schoepfer J; García-Echeverría C; Einsele H; Wajant H; Bargou RC
    Leukemia; 2008 Aug; 22(8):1604-12. PubMed ID: 18480838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.
    Hsueh YS; Chang HH; Chiang NJ; Yen CC; Li CF; Chen LT
    Oncotarget; 2014 Nov; 5(22):11723-36. PubMed ID: 25375091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers.
    Radhakrishnan H; Ilm K; Walther W; Shirasawa S; Sasazuki T; Daniel PT; Gillissen B; Stein U
    Cancer Lett; 2017 Sep; 403():231-245. PubMed ID: 28649004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein.
    Han Y; Park S; Kinyua AW; Andera L; Kim KW; Kim I
    Oncol Rep; 2014 Jan; 31(1):456-62. PubMed ID: 24213797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer.
    Xue N; Lai F; Du T; Ji M; Liu D; Yan C; Zhang S; Yu X; Jin J; Chen X
    Cell Mol Life Sci; 2019 Sep; 76(17):3433-3447. PubMed ID: 30980109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
    Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
    Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
    Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
    Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
    Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
    Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
    Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.